Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;3(2):64-74.
doi: 10.1016/j.ajur.2016.02.004. Epub 2016 Mar 2.

Advances in prostate cancer research models: From transgenic mice to tumor xenografting models

Affiliations
Review

Advances in prostate cancer research models: From transgenic mice to tumor xenografting models

Yuejiao Huang et al. Asian J Urol. 2016 Apr.

Abstract

The identification of the origin and molecular characteristics of prostate cancer (PCa) has crucial implications for personalized treatment. The development of effective treatments for PCa has been limited; however, the recent establishment of several transgenic mouse lines and/or xenografting models is better reflecting the disease in vivo. With appropriate models, valuable tools for elucidating the functions of specific genes have gone deep into prostate development and carcinogenesis. In the present review, we summarize a number of important PCa research models established in our laboratories (PSA-Cre-ERT2/PTEN transgenic mouse models, AP-OX model, tissue recombination-xenografting models and PDX models), which represent advances of translational models from transgenic mouse lines to human tumor xenografting. Better understanding of the developments of these models will offer new insights into tumor progression and may help explain the functional significance of genetic variations in PCa. Additionally, this understanding could lead to new modes for curing PCa based on their particular biological phenotypes.

Keywords: Prostate cancer; Transgenic mouse lines; Translational medical systems; Tumor xenografting models.

PubMed Disclaimer

References

    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Kwak J.T., Hong C.W., Pinto P.A., Williams M., Xu S., Kruecker J. Is visual registration equivalent to semiautomated registration in prostate biopsy? Biomed Res Int. 2015;2015:394742. - PMC - PubMed
    1. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45. - PubMed
    1. Wu W., Liu X., Chaftari P., Cruz Carreras M.T., Gonzalez C., Viets-Upchurch J. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015;10:e0122047. - PMC - PubMed
    1. Powers G.L., Hammer K.D., Domenech M., Frantskevich K., Malinowski R.L., Bushman W. Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Mol Cancer Res. 2015;13:149–160. - PMC - PubMed